LON:OPTI

OptiBiotix Health Final Earnings Report

OptiBiotix Health logo
GBX 6.18 +0.24 (+3.95%)
As of 11:46 AM Eastern

OptiBiotix Health EPS Results

Actual EPS
-GBX 3.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OptiBiotix Health Revenue Results

Actual Revenue
$1.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OptiBiotix Health Announcement Details

Quarter
Final
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OptiBiotix Health Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More OptiBiotix Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptiBiotix Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiBiotix Health and other key companies, straight to your email.

About OptiBiotix Health

OptiBiotix Health (LON:OPTI) (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

View OptiBiotix Health Profile